Captrust Financial Advisors Cuts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Captrust Financial Advisors lessened its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 8.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 9,425 shares of the specialty pharmaceutical company’s stock after selling 819 shares during the quarter. Captrust Financial Advisors’ holdings in Supernus Pharmaceuticals were worth $294,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Segall Bryant & Hamill LLC acquired a new position in Supernus Pharmaceuticals during the 3rd quarter worth approximately $791,000. Renaissance Technologies LLC lifted its holdings in Supernus Pharmaceuticals by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after buying an additional 351,900 shares during the last quarter. Bank of Montreal Can boosted its holdings in Supernus Pharmaceuticals by 1,508.0% in the second quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock valued at $3,287,000 after purchasing an additional 109,088 shares in the last quarter. Candriam S.C.A. acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $3,795,000. Finally, Stephens Investment Management Group LLC boosted its stake in Supernus Pharmaceuticals by 1.8% in the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock valued at $60,246,000 after acquiring an additional 33,710 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SUPN. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $36.17 on Friday. The business has a 50 day moving average price of $35.30 and a 200 day moving average price of $31.94. The company has a market capitalization of $2.00 billion, a P/E ratio of 33.80 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same quarter in the previous year, the company posted ($0.29) EPS. The business’s revenue was up 14.2% on a year-over-year basis. On average, research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Insider Transactions at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the completion of the sale, the senior vice president now directly owns 8,200 shares in the company, valued at $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jack A. Khattar sold 125,000 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the transaction, the chief executive officer now directly owns 926,172 shares in the company, valued at $33,971,988.96. The trade was a 11.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 154,213 shares of company stock valued at $5,660,180 in the last ninety days. Corporate insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.